M1 Group

EQS-News: M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024

Retrieved on: 
Friday, February 16, 2024
M1, EUR, Growth, Frankfurt Stock Exchange, Policy, M1 Group

M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024

Key Points: 
  • M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024
    Berlin, 16 February 2024 - M1 Kliniken AG (ISIN: DE000A0STSQ8) has built up the leading private aesthetic medical service provider in Europe under the "M1 Med Beauty" brand.
  • In the first nine months of 2023, the Beauty segment generated revenue of EUR 53.2 million (+28.5 %) and EBITDA of EUR 16.9 million (+56.6 %).
  • The analysts' forecasts for the current financial year 2024 of M1 Kliniken AG amount to an EBITDA of EUR 27.1 million, an estimate that is also shared by the M1 Management Board.

EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

Retrieved on: 
Saturday, December 30, 2023
Growth, EUR, M1, M1 Group, Lithium

M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

Key Points: 
  • M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG publishes figures for the third quarter 2023:
    Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).
  • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).
  • EBIT rose by 98.2% to EUR 12.94 million (previous year: EUR 6.53 million), an increase of EUR 6.4 million.

Myanmar Telecoms Industry Report 2023-2030: Mobile Subscriptions Expanding but at a Slower Pace

Retrieved on: 
Thursday, November 9, 2023
SIM, EBITDA, Research, Telenor, Internet of things, MPT, Mytel, Telecommunications, Investment, FTTH, Apollo Tower, Public expenditure, Virtual reality, Atom, Ooredoo, Pan-Asia, M1 Group, Cloud computing, Growth, Population growth, EV, Quality of life, Tourism, Video game, Financial services

DUBLIN, Nov. 9, 2023 /PRNewswire/ -- The "Myanmar Telecoms Industry Report - 2023-2030" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 9, 2023 /PRNewswire/ -- The "Myanmar Telecoms Industry Report - 2023-2030" has been added to ResearchAndMarkets.com's offering.
  • Myanmar was among the fastest developing telecommunications markets in the world, mainly driven by the late investments from 2014 onwards.
  • The report forecasts the total Myanmar telecom market to grow at an average annual rate of 2.9% from 2023-2030, reaching USD 2.3 billion by 2030.
  • Myanmar's mobile market will continue expanding over the next decade, fueled by population growth, smartphone adoption, and consumers' shift to mobile data.

EQS-News: M1 Kliniken AG Acquires Online Pharmacy and Secures Long-Term Procurement Advantages

Retrieved on: 
Thursday, December 14, 2023
ISIN, EBIT, Acquisition, Health, M1 Group, Growth, Pharmaceutical industry, Maasbree

Increasing value creation and margin improvement, as well as ensuring the supply of aesthetic pharmaceuticals to medical treatment centers through the acquisition of a Dutch online pharmacy.

Key Points: 
  • Increasing value creation and margin improvement, as well as ensuring the supply of aesthetic pharmaceuticals to medical treatment centers through the acquisition of a Dutch online pharmacy.
  • Berlin, November 24, 2023 – By acquiring the German Nutri Care GmbH and its wholly-owned subsidiary, the Dutch online pharmacy "Direct Apotheke Venlo B.V.," M1 Kliniken AG (ISIN: DE000A0STSQ8) taps into a significant growth field and expands the value chain of its health services.
  • Direct Apotheke Venlo B.V., based in Maasbree (NL), is one of the rapidly growing providers in the online pharmacy business for aesthetic pharmaceuticals, with current core markets in Germany and the Netherlands.
  • "As we continue to internationalise our specialist centres network in Europe, we anticipate significant growth in the online pharmacy business.

EQS-News: M1 Kliniken AG publishes figures for the first half year 2023:

Retrieved on: 
Thursday, August 31, 2023
Annual, Supervisory board, EBIT, M1 Group, EUR, Federal Executive Boards, EBITDA, Supervision, ISIN, Growth, M1, Beauty salon, Film industry, Lithium, Beauty

M1 Kliniken AG publishes figures for the first half year 2023:

Key Points: 
  • M1 Kliniken AG publishes figures for the first half year 2023:
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG publishes figures for the first half year 2023:
    Further growth and disproportionate increase in operating result.
  • Accordingly, the consolidated group revenue of the M1 Group increased by 8.7% to EUR 150.8 million in the first half of the year (previous year: EUR 138.7 million).
  • Consolidated EBITDA of the M1 Group totalled EUR 9.9 million in the first half of 2023 (previous year: EUR 7.4 million), an increase of around 35 %.

EQS-News: MPH Health Care AG: Q1 result 2023

Retrieved on: 
Saturday, June 10, 2023
News, Housing, Frankfurt Stock Exchange, AG, NAV, EBIT, Sale, EUR, Acquisition, Investment, M1 Group, ISIN, CR, Management, MPH, Security (finance), Lithium

Preliminary IFRS result for the first quarter of 2023 published.

Key Points: 
  • Preliminary IFRS result for the first quarter of 2023 published.
  • Berlin, 6 June 2023 - MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated result for the first quarter of 2023.
  • The IFRS result for the first quarter of 2023 was EUR -33.4 million (previous year EUR -3.9 million).
  • MPH can also benefit systematically from the positive developments of the investments in the coming years ", says Patrick Brenske, MPH Board of Management member.

EQS-News: M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result

Retrieved on: 
Thursday, June 1, 2023
ISIN, EUR, EBITDA, M1 Group, EBIT, Annual general meeting, Beauty salon, Lithium, Film industry, Beauty

M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result

Key Points: 
  • M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG publishes Q1 figures 2023:
    Strong growth and disproportionate increase in operating result.
  • Consolidated EBITDA of the M1 Group totalled EUR 5.3 million in Q1 2023 (previous year: EUR 4.2 million), an increase of around 26%.
  • The international beauty markets posted sales of EUR 2.8 million and EBIT of EUR -0.5 million (Q1 2022: EUR -0.4 million).

EQS-News: MPH Health Care AG: Preliminary IFRS result 2022

Retrieved on: 
Friday, April 28, 2023
Beauty, Housing, Frankfurt Stock Exchange, COVID-19, Tax, Clinical trial, AG, NAV, EBIT, M1 Group, Investment, ISIN, MPH, Security (finance), Euro

Berlin, 27 April 2023 - MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated result for the 2022 financial year.

Key Points: 
  • Berlin, 27 April 2023 - MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated result for the 2022 financial year.
  • In the 2022 financial year, the preliminary IFRS net income amounted to Euro 29.1 million (previous year net loss of Euro 9.0 million).
  • As of 31 December 2022, equity increased by Euro 29.1 million to Euro 221.4 million (previous year Euro 192.3 million).
  • According to the preliminary figures for the 2022 financial year, EBIT increased from Euro 66 million to Euro 76 million.

EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022

Retrieved on: 
Thursday, April 20, 2023
ISIN, COVID-19, Clinical trial, M1 Group, Investment, Beauty salon, Pharmaceutical industry, Tourism, Cryptocurrency, Beauty, EBIT

M1 Kliniken AG publishes preliminary figures for financial year 2022:

Key Points: 
  • M1 Kliniken AG publishes preliminary figures for financial year 2022:
    Profitable revenue growth in the Beauty segment of more than 14%; increase in EBIT margin in the Beauty segment from 9.8% to around 12%; Group equity rises to €143.1 million; free cash flow of €19.0 million.
  • Berlin, 20.04.2023 –M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2022.
  • The consolidated group turnover of the M1 Group decreased by around 9% to €285.3 million in the 2022 financial year (previous year €314.6 million).
  • In the 2022 financial year, a high operating cash flow of €20.8 million was again generated (previous year €15.7 million).

EQS-News: M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market

Retrieved on: 
Sunday, November 27, 2022
Growth, M1 Group, EBITDA, Bed, ISIN, EBIT, COVID, Clinical trial, EUR, Investment, Film, M1, Beauty

M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market

Key Points: 
  • M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market
    Group EBITDA amounts to EUR 10.9 million (previous year: EUR 12.0 million); EBIT amounts to EUR 6.5 million (previous year: EUR 7.8 million)
    Berlin, 14.11.2022 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces key financial figures for the period Jan - Sep 2022.
  • Accordingly, consolidated group sales for the first nine months amounted to EUR 214 million (previous year: EUR 236 million).
  • With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.